Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LuPARP: 177Lu-PSMA-617 and Olaparib in mCRPC
NCT03874884Phase 1Active, not recruiting
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Jul 2019
- Primary completion
- May 2025
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of olaparib and lutetium lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Peter MacCallum Cancer Centre. Primary endpoints: Dose Limiting Toxicities at 11 months, Maximum Tolerated Dose at 11 months and 1 more. Started Jul 2019; status: active, not recruiting.
02
Drugs
olapariblutetium lu 177 vipivotide tetraxetan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03874884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03874884.